Statin use increases the risk of osteoarthritis and joint pain by 26%

This study was published in the American Journal of Medical Sciences 2013 May;345(5):343-8

 

Study title and authors:

Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis.

Mansi IA, Mortensen EM, Pugh MJ, Wegner M, Frei CR.

Brooke Army Medical Center, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78234-6200, USA. Iishak.mansi@us.army.mil

 

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/22975580

This study was conducted to investigate the incidence of various musculoskeletal diseases in statin users and nonusers. The study included 12,980 statin users and 45,997 nonusers who were followed for four years.

The study found:
(a) Statin users had a 26% increased risk of osteoarthritis and arthropathy (joint pain) compared to non-users.
(b) Statin users had a 20% increased risk of dorsopathies (back or spinal pain), rheumatism (joint and connective tissue problems) and chondropathies (cartilage disease) compared to non-users.

Statins increase the risk of serious adverse cardiovascular events

This study was published in the Journal of the American Medical Association 2007 Mar 28;297(12):1344-53

 

Study title and authors:

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.

Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group.

Department of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA. jrcrouse@wfubmc.edu

 

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/17384434

This study investigated the effects of statins in participants with a low risk of heart disease. The two year study was a randomised, double-blind, placebo-controlled trial of 984 individuals, average age 57 years. The participants received either a daily 40-mg dose of rosuvastatin or placebo.

The study found:
(a) Cholesterol levels reduced by 33% in the statin users and remained the same in those on placebo.
(b) Low density lipoprotein (LDL) cholesterol levels reduced by 49% in the statin users and remained the same in those on placebo.
(c) Statin users had a 21% increased risk of death compared to placebo.
(d) Statin users had a 423% increased risk of a serious adverse cardiovascular event compared to placebo.
(e) Statin users had a 4% increased risk of any adverse event compared to placebo.
(f) Statin users had a 5% increased risk of developing cancer compared to placebo.
(g) Statin users had a 5% increased risk of muscle pain compared to placebo.
(h) Statin users had a 121% increased risk of elevated liver enzymes compared to placebo.
(i) Statin users had a 56% increased risk of developing arthritis compared to placebo.